Celularity Inc (CELU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.68-8.20%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CELU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -87.6% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 27.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
CELU — officer change
Dated 2026-08-07
Chief Commercial Officer — Rick Gonzalez: The employment of Rick Gonzalez, the Company’s Chief Commercial Officer, was terminated immediately.
Why it matters: This shows if Celularity's revenue growth is slowing. This could affect investor confidence.
Worry ifQ2 revenue growth reported below 10% year over year.
Less concerning ifQ2 revenue growth reported above 10% year over year.
Why it matters: Selling cenplacel-L is important for making more money. Recent revenue fell a lot.
Supportive ifCenplacel-L revenue increases to over $10 million in the next quarter.
Worry ifCenplacel-L revenue is under $4 million. This shows ongoing problems with sales.
Why it matters: A successful sale could help focus and improve finances. It shows management's plan to change.
Supportive ifA news release about a sale or deal in the biomaterials business.
Worry ifNo progress or further delays in the divestiture process.
Why it matters: Milestone payments would improve cash flow and prove the value of the NexGel deal.
Supportive ifCelularity says it received milestone payments from NexGel. These payments are based on sales goals.
Worry ifNo milestone payments mean NexGel is not performing well in sales.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$271 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $897 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,519 loss on $10,000 · 75.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Fixing compliance issues is key to keeping the company's listing and investor trust.
Worry ifCompany gets notice that it meets Nasdaq's $35 million market value rule.
Less concerning ifMore notices from Nasdaq about non-compliance or drops in market value.
Why it matters: New agreements can show growth and partnerships. These may boost the company's market position.
Supportive ifManagement says they have a new important deal with a big partner.
Worry ifNo new agreements or delays in current talks.
Why it matters: Fixing the Nasdaq listing issue is key for Celularity's market presence. It affects investor trust and funding.
Worry ifCelularity shares a plan to meet the $35 million market value.
Less concerning ifMore notices from Nasdaq about listing problems.
Why it matters: Revenue from these products shows how well Celularity's new strategy is working. It tells us if the market likes their regenerative therapies.
Supportive ifCenplacel-L and Lifebank made more than $1 million together in Q3 2026.
Worry ifCombined revenue from cenplacel-L and Lifebank is below $500,000 in Q3 2026.
Why it matters: More Lifebank sales can show demand for cellular banking. This fits Celularity's bigger plan.
Supportive ifLifebank sales grow by more than 15% year over year in the next quarter.
Worry ifIf Lifebank sales drop or stay the same, it shows weak market interest.
Why it matters: Completing the sale shows that management is making progress. This is important for growth.
Supportive ifA press release will confirm the sale of the biomaterials business for at least $13.3 million.
Worry ifNo announcement or delays in the divestiture process beyond the next quarter.
Why it matters: The new CEO's plans could change the company's path. Good changes may help performance, but bad ones could hurt growth.
Watch forCelularity has better operations since the new CEO started. They also have new plans.
Also watch forIf performance stays poor or plans are unclear after the change, it could be a problem.
Why it matters: A new CCO can bring fresh strategies to boost sales for cenplacel-L and Lifebank.
Supportive ifA press release says there is a qualified candidate for the CCO job.
Worry ifNo new appointment is made by the end of Q4 2026.
Why it matters: Following Nasdaq rules is important. It helps keep the company's listing and investor trust.
Worry ifA press release confirms that Nasdaq's minimum bid price rule is being followed.
Less concerning ifAnother notice of delisting was issued. This is due to ongoing non-compliance.